EGFR antibodies, such as cetuximab, demonstrate superior clinical efficacy in colorectal cancer (CRC) compared to EGFR-TKIs, which are primarily used in non-small cell lung cancer (NSCLC) with activating EGFR kinase domain mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.